Clinical Research Directory
Browse clinical research sites, groups, and studies.
Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients
Sponsor: Baylor Research Institute
Summary
This phase II, multi-center, open-label study will evaluate the safety and efficacy of utilizing HCV-positive donors for heart transplant in HCV-negative recipients treated with sofosbuvir 400 mg / velpatasvir 100 mg (Epclusa®).
Key Details
Gender
All
Age Range
18 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2018-03-20
Completion Date
2026-12-30
Last Updated
2026-01-22
Healthy Volunteers
No
Conditions
Interventions
Epclusa
If and when these recipients develop confirmed viremia by HCV PCR, Epclusa® therapy will be administered for a 12-week course.
Locations (3)
Cedars-Sinai Medical Center
Los Angeles, California, United States
Duke University Medical Center
Durham, North Carolina, United States
Baylor University Medical Center
Dallas, Texas, United States